Finally, to our knowledge, almost all biomarkers that have been reproduced sufficiently to be used in clinical practice (e.g., CSF Aβ42 and P-tau for AD, and RT-QuIC for CJD) have been discovered with a grounded theory, based on a clear hypothesis about disease mechanisms. This evidence concerns the gene MAPT and Alzheimer disease.